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ABSTRACT
Background Anxiety disorders are widespread in patients with chronic diseases such as rheumatoid arthritis (RA). This paper targets the cost-
effectiveness analysis of a cognitive-behavioral group therapy (CBT) in comparison to a client-centered, supportive-experiential group therapy
(SET) in arthritis patients with dysfunctional fear of progression.
Methods From the societal perspective, direct costs were compared with the reduction of fear of progression over time. Means, their 95%
confidence intervals (95% CI), the incremental cost-effectiveness graphic and the acceptability curve were obtained using 1000 non-
parametric bootstrap replications.
Results A total of 174 RA patients were included in the economic evaluation. The estimated means (95% CI) of direct costs and reduction of
fear of progression were, respectively, E7945.34 (5075.59; 11335.08) and 0.25 (20.48; 0.99) for patients in the SET and 5619.25 E
(3950.67; 7708.52) and 0.94 (0.29; 1.62) for patients in the CBT. As the majority of the cost-effect pairs after bootstrap analysis were located
in the southeast quadrant of the cost-effectiveness plane, the CBT can be considered a dominant intervention.
Conclusion The main result of our study is the higher cost-effectiveness of CBT in comparison to SET in RA patients with dysfunctional fear
of progression.
Keywords cognitive behavior therapy, cost-effectiveness, economics, health resource, rheumatoid arthritis
Introduction
Anxiety disorders are widespread in patients with chronic
diseases such as rheumatoid arthritis (RA).1,2 In a recent
study in Germany either a depressive or anxiety disorder
was diagnosed in 24.3% of patients with inﬂammatory rheu-
matic diseases.3 In addition to the burden to patients and
their families, fear and anxiety associated with medical con-
ditions have important socio-economic consequences as
high health care use costs and an important reduction of the
work capacity.4–6 In Germany, high indirect annual costs of
an average $11 750 were identiﬁed among RA patients.7
Consequently, interventions, which can reduce fear and
anxiety of patients suffering from chronic conditions, would
not only beneﬁt patients directly, but could also contribute
to the reduction of the economic burden to society.
To our knowledge, chronic arthritis patients with fear of
progression undergoing inpatient rehabilitation in Germany
receive no structured psychological therapy. However, fear
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of progression is potentially amendable to cognitive-
behavioral therapies (CBT): a recent study by Herschbach
found a statistically signiﬁcant long-term reduction of fear
of progression in cancer patients after CBT as well as after a
client-centered, supportive-experiential group therapy (SET),
but not among chronic arthritis patients.7,8 However, CBT
for patients with generalized anxiety disorders is cost-
effective.8,9 Additionally, a recent study shows that RA
patients had statistically signiﬁcant lower health-care use
after CBT.10 It would be therefore important from a societal
perspective to demonstrate whether CBT can also result in a
reduction of direct medical and indirect costs in the RA
patients with dysfunctional fear of progression. More
speciﬁcally, a hypothesis can be formulated as to whether
CBT can be more cost-effective than SET.
However, there is a lack of economical evaluations
investigating the cost-effectiveness of psychotherapeutic
interventions for RA patients with anxiety disorders. The
objective of our study therefore was to perform an
incremental cost-effectiveness analysis of the results of the
randomized controlled trial (RCT) published by Herschbach
et al.11 comparing a CBT focusing on fear of progression to
client-centered SET.
Materials and methods
Study design
We performed an economic evaluation alongside an RCT.
One hundred and seventy-four RA participants were
recruited between November 2002 and December 2003 in
one rehabilitation clinic in the region of Bavaria, Germany.
Patients willing to participate were allocated to an interven-
tion arm using external randomization and were blind with
regard to group assignment. The inclusion criteria of the
study were: RA, minimum age 18 years old, inpatient rehabi-
litation and increased fear of progression measured with the
standardized fear of progression questionnaire.12 Patients
were excluded for having cognitive impairment, being bed-
ridden or poor command of the German language. Patients
were assessed at baseline, post-intervention and at the
3- and 12-month follow-up after discharge.11
Interventions
All patients underwent the same 3-week inpatient rehabilita-
tion program. In addition to the standard rehabilitation
program, patients in both CBT and SET groups received
four sessions of group psychotherapy, each lasting 90 min.
The sessions were led by trained psychotherapists and all
sessions were supervised. Both CBT and SET were
manualized with regard to structure but content (topics and
intervention) was predeﬁned solely in CBT. While the CBT
was a directive and speciﬁc intervention aimed at confront-
ing patients with their fears and at learning to cope with
them, the SET was a client-centered, supportive-experiential
group therapy intervention based on the work of Carl
Roggers.11 The SET was a non-directive and unspeciﬁc
intervention focusing on emotional expression, mutual
support and reassurance, and social comparison.11
Health-care utilization and costs
The economic evaluation was performed from the societal
perspective. As this study was conducted over a 1 year
period, costs and effects were left undiscounted.
Incremental interventions costs were calculated based on the
duration of the therapy modules, group size and the minute
salaries of psychologists. Following Guidelines of the
Working Group Methods in Health Economic Evaluation
(AG MEA),13–15 a 20% charge was added to the calculated
costs because of the time spent learning the manuals, pre-
paring the sessions and conducting supervisions.
Patients of SET and CBT completed a retrospective
health-care resource use assessment questionnaire at baseline
and 12 months after rehabilitation. The questionnaire was
developed following the guidelines proposed by the AG
MEA.13–15 Resource use volumes were combined with unit
costs to obtain a net cost per patient over the entire period.
If resource use was obtained for recall periods shorter than
12 months, resource use data were extrapolated to obtain
annual ﬁgures. Direct medical costs included visits to prac-
titioners, non-physician service utilization, hospital treat-
ments, day care, medication, devices and aids. Direct
non-medical costs included leisure time loss of patients due
to participation on self-help groups and of parents or
friends due to the voluntary assistance of the patient.
Indirect costs were assessed using the human capital
approach and were calculated based on sick leave days. All
costs were calculated in euros.
Effectiveness data
We report means and standard deviations of the fear of pro-
gression score and of the mental scale of the SF12 estimated
in the original RCT.
Cost-effectiveness analysis
We performed an incremental cost-effectiveness analysis
(CEA) comparing both intervention groups (CBT and SET)
and calculated the incremental cost-effectiveness ratio
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(ICER), i.e. the difference in average costs divided by the
difference in average effects between these two groups.
Indirect costs were not included in the CEA because of
51.15% missing values with regard to sick leave in the
follow-up. Costs were the mean direct costs (medical and
non-medical) within the ﬁrst year after discharge.
Effectiveness was measured with the standardized fear of
progression questionnaire, which comprises 43 items relating
to 5 dimensions: affective reactions, partnership/family,
occupation, loss of autonomy and coping with anxiety. We
used as an effectiveness measure of the total score, i.e. the
sum of the subscales’ mean scores excluding the coping
scale. This score has a range of values between 4
(minimum) and 20 (maximum).12,16 The mean fear of pro-
gression at the 12-month follow-up minus the mean fear of
progression at baseline was used as an effectiveness
measure. As a reduction of the fear of progression was
aimed, effectiveness is expected to have negative ﬁgures.
However, negative effectiveness measures in CEA are inter-
preted as being less effective. Owing to this fact we multi-
plied the effectiveness regarding the outcome fear of
progression by negative 1 in order to get positive ﬁgures in
the event of more effects.
In order to increase the comparability of this study to the
literature, we also performed an incremental CEA using the
mental score of the questionnaire for general health status
(SF12) at the 12-month follow-up as the effect outcome.17
The mental score of the SF12 was chosen for comparison
because of its close association with the Fear of Progression
Questionnaire.12
Unit costs
All costs were calculated for the year 2004 (Table 1).
Medication was valuated on the basis of prices of the
online German drugs index book.18 Devices and aids were
valuated with prices charged by the health insurance society
of Bavaria.19 Day-care treatment was purchased with prices
charged in 2004 at the University of Munich Hospital. All
other index costs were proposed by the AG MEA.13–15
The proposed index costs were originally estimated for the
year 2001. We extrapolated the unit costs for 2004 using a
factor of 0.025 for the ﬁrst year and 0.020 for the following
years as suggested by the AG MEA.
Statistical analysis
We used non-parametric bootstrap techniques with 1000
replications to estimate mean values and 95% conﬁdence
intervals (95% CI). In order to compare the means of the
groups, we calculated the achieved signiﬁcance level (ASL)
using bootstrap-t methods. The achieved signiﬁcance level
corresponds to the P-value of a t-test and will be called pboot
here.20 Because of multiple testing a probability P-value of
less than 0.005 with Bonferroni correction (0.05/9) was
considered signiﬁcant. The uncertainty surrounding the esti-
mates of the cost-effectiveness was illustrated by a cost-
effectiveness acceptability curve (CEAC). The threshold
value payers are willing to pay for a new intervention is
usually not known. Therefore, in the CEAC probabilities of
superior cost-effectiveness of CBT compared with SET are
calculated for an arbitrary range of potential threshold
Table 1 Prices applied in the economic evaluation
Cost categories Price
(E)
Cost categories Price (E)
Physician visitsa Daycare treatment
General practitioner 16.03 Internal medicine 252.00
Neurologist 23.02 Surgical 484.00
Internist 34.62 Gynecology 175.00
Orthopedist 23.43 Neurology 269.00
Rheumatologist 30.18 Radiology 235.00
Physical medicine 270.00
Oncology 575.00
Pain unit 285.00
Inpatient treatmentb Outpatient treatment
(hospital)
Internal medicine 310.62 Gastroenterology 23.02
Surgical 349.55 Gynecology 26.88
Gynecology 377.33 Surgical 22.94
Gastroenterology 358.45 Urology 28.88
Urology 374.03 Dermatology 15.63
Dermatology 332.87 Internal medicine 34.62
Neurology 357.34 Orthopedic 23.43
Orthopedic 275.02 Cardiology 61.79
Cardiology 348.44 Radiology 83.54
Radiology 416.30 Pneumology 37.82
Rehabilitation oncology 105.00 Rheumatology 30.18
Rehabilitation orthopedic 102.00 Psychology 47.51
Mean value 390.00 Mean value 23.02
Psychotherapyc 47.51 Self-help groups
(patient hour price)
17.80
Physiotherapy 21.89 Time of relatives
(hour price)
17.80
Massage 9.70 Sick leave daysd 89.00
Ergotherapy 29.00 Psychologist minutee 0.4910
aPrice per visit.
bPrice per day.
cPrice per session.
dPrice of a calendar day.
eSalary of a rehabilitation clinic staff.
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values that decision-makers could be willing to pay for the
implementation of CBT. The mean costs and mean effects
distributions obtained from the 1000 replications were used
to plot the incremental cost-effectiveness graphic and the
CEAC. As the distribution of the bootstrap estimates of
costs and effects was symmetric, we use the percentile
method to calculate CI.21
Uncertainty in the cost and effectiveness estimates can be
allowed by sensitivity analysis, statistical inference or some
combination of the two approaches.22 We addressed the
uncertainty presenting CI obtained from bootstrap samples
and estimating acceptability curves for the ICERs.23 All stat-
istical calculations inclusive of the bootstrap procedure, the
estimation of the incremental cost-effectiveness graphics and
the CEAC were performed using SPSS version 14.0.
Results
Study population
Health resource use data were collected for 174 patients ran-
domized either in the CBT (n ¼ 87) or in the SET (n ¼ 87)
group. The average age of patients in the SET and in the
CBT groups was 47.45 (SD 8.91) and 45.43 (SD 9.75),
respectively. The percentage of male participants was 23%
in the SET and 31% in the CBT group. At baseline, 79.3%
of SET and 75.8% of CBT participants were employed.
Complete indirect cost data of at baseline employed patients
were available at the 12-month follow-up for 89 patients (37
SET; 52 CBT). As described elsewhere, patients of both
groups were comparable to sociodemographic character-
istics, disease severity and comorbidities.24
Dropouts
By the 12-month follow-up 55 patients (34 SET and 21
CBT) had dropped out: 18.2% did not want to participate
anymore, 9.1% could no be contacted anymore, 72.8% did
not return the case record form. Drop outs were very
similar to participants considering age, sex and employment
status. Participants and drop outs incurred similar direct
medical costs at baseline but drop outs on average incurred
higher indirect costs [E6108.21 (95% CI: 3484.54; 8731.87)]
than participants [E4214.41 (95% CI: 2894.88; 5533.93)].
Health-care utilization and costs
Both CBT and SET were performed as an additional
therapy module to a standard 3-week inpatient rehabilitation
program. The incremental cost of adding either CBT or
SET to a standard 3-week inpatient rehabilitation program
was about E47 per patient or E282 per group.
Patients of the CBT at the 12-month follow-up had fewer
internist visits, fewer inpatient days, fewer day-care treat-
ments, used fewer aids and devices, lower medication costs,
fewer sick leave days and required less care giving from
friends/relatives than patients of the SET. CBT subjects on
average had at the 12-month follow-up fewer direct medical,
direct non-medical and indirect costs as subjects who
received SET but these differences were non-signiﬁcant
(P ¼ 0.237, P ¼ 0.381 and P ¼ 0.350, respectively)
(Table 2). Non-signiﬁcant pre–post cost differences could
be found in both groups. However, direct medical costs
increased in both groups, mainly due to a substantial
increase of medication costs. Patients of the SET also had
more inpatient days, day-care treatment days and psy-
chotherapies sessions in the follow-up.
Effectiveness data
The fear of progression mean score was at baseline 12.4
(2.6) in the CBT and 12.5 (2.5) in the SET group. At the
12-month follow-up, the fear of progression mean score was
11.4 (2.8) in the CBT and 11.8 (2.7) in the SET group.
Regarding the mental score of the SF12, the mean scores at
the baseline were 39.8 (10.9) and 38.5 (9.3) and at the
12-month follow-up 41.6 (9.4) and 40.2 (9.3) in the CBT
and SET groups, respectively.
Table 2 Mean (95% CI) costs (in the last 12 months) at baseline and at the 12-month follow-up
Direct medical costs Baseline 12-month follow-up P-value
SET (n ¼ 87) 4562.93 (3199.86; 6327.93) 6205.07 (3712.74; 9264.95) pboot ¼ 0.532
CBT (n ¼ 87) 3176.61 (2684.76; 3730.42) 4324.86 (2928.20; 6005.44) pboot ¼ 0.183
SET (n ¼ 87) 1801.61 (956.62; 3138.96) 1748.43 (901.30; 2883.40) pboot ¼ 0.424
CBT (n ¼ 87) 1612.86 (1067.10; 2262.52) 1212.16 (644.25; 1946.77) pboot ¼ 0.636
SET (n ¼ 72) 5120.58 (3457.38; 6895.82) 6562.07 (2871.20; 10650.62) pboot ¼ 0.200
CBT (n ¼ 76) 4392.97 (3042.55; 5936.39) 4526.00 (2395.13; 7017.97) pboot ¼ 0.538
Means and CI calculated with 1000 bootstrap replications. Costs are presented in euros.
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Cost-effectiveness analysis
Both direct costs and reduction of fear of progression data
were available for 100 patients. The estimated means (95%
CI) of direct costs and reduction of fear of progression
were, respectively, E7945.34 (5075.59; 11335.08) and 0.25
(20.48; 0.99) in SET and E5619.25 (3950.67; 7708.52) and
0.94 (0.29; 1.62) in CBT. Figure 1 shows the cost-
effectiveness plane with the (95% CI) of the ICER. The
difference (95% CI) in effects and direct costs amounted to
0.69 (20.21; 1.67) and to 2E2326.09 (26167.26;
1047.12), respectively. CBT is therefore from a societal per-
spective a dominant intervention (less costly, more effective),
with the resulting ICER (95% CI) amounting to minus
E3371.14 (236533.54; 25916.96) for an additional unit of
effect. Given the acceptability curve there is a 90.2% chance
that CBT, compared with the SET, is cost-effective without
a need for additional costs to payers, i.e. there is a prob-
ability of 90.2% that the ICER is negative, meaning that
CBT is less costly and more effective (Fig. 2).
Both direct costs and quality of life data were available for
44 patients of the SET and 55 patients of the CBT. The esti-
mated means (95% CI) of all direct costs and of the SF12
mental scale were E8711.40 (5841.80; 12292.26) and 39.34
(36.42; 42.20) in SET and E5619.25 (3950.67; 7708.52) and
42.57 (40.11; 45.35) in CBT, resulting into a negative ICER
(95% CI) amounting to minus E960.29 (26991.71;
2274.18) for an additional unit of effect. The majority of the
cost-effect pairs after bootstrap analysis were located in the
southeast quadrant (plane not shown), suggesting that CBT
is a dominant alternative. Given the acceptability curve
(ﬁgure not shown) there is a 94.8% chance that CBT, com-
pared with SET, is cost-effective without the need for
additional costs to payers. As the close association between
the Fear of Progression Questionnaire and the SF-12 also
suggests a strong impact of fear of progression on overall
quality of life, the similar results are not surprising.12
Discussion
Main finding of this study
In a recent RCT aiming to treat RA patients with elevated
levels of fear of progression, no statistic signiﬁcant long-
term effects of CBT or SET could be shown.24 Our objec-
tive was to perform an incremental cost-effectiveness analy-
sis of the results of this RCT published by Herschbach. The
main result of our study is the higher cost-effectiveness of
CBT in comparison to SET in RA patients.
What is already known on this topic
Currently, arthritis patients with dysfunctional fear of
progression undergoing inpatient rehabilitation in Germany
receive no psychological group therapy targeting FoP.
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Figure 1 Incremental cost-effectiveness plane. Costs are direct costs in euros (medical and non-medical) within the first year after discharge. Effects are the
reduction of fear of progression within the first year after discharge. Cost and effect pairs were estimated with 1000 bootstrap replications.
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Although our CBT subjects had in the follow-up fewer
direct and indirect costs as subjects who received SET, we
failed to ﬁnd statistically signiﬁcant between-group differ-
ences. Similar results have been reported in the literature.
An RCT of the arthritis self-management program also
found no statistically signiﬁcant between-group differences
in health-care utilization of patients as RA, osteoarthritis or
ﬁbromyalgia.25 Also Schweikert’s recent study, which comes
very close to us in design and intervention but focuses on
back pain disorders, found no statistically signiﬁcant differ-
ences between intervention and control group regarding
direct costs.26
Although CBT might improve productivity, few studies
report data on indirect costs. A recent review targeting the
economical impact of CBT in the treatment of mental dis-
orders identiﬁed 22 cost-effectiveness studies but only four
reported productivity loss data.8 In our study, a trend
towards fewer sick leave days and less indirect costs could
be observed in CBT group. We suppose therefore a positive
impact of the intervention on sick leave. However, due to
many missing values in the follow-up, we are not able to
make reliable statements. A similar study for patients with
chronic low back pain also reported less indirect costs in the
intervention group but the difference was in a similar way
statistically non-signiﬁcant.26
What this study adds
While the cost-effectiveness of CBT for patients with
mental disorders was often addressed, few economic evalu-
ations targeted the economic impact of CBT in patients
with chronic physical diseases such as RA. Two economic
evaluations targeting the cost-effectiveness of adding CBT
to a rehabilitation program for patients with chronic back
pain came to the conclusion, the addition of CBT does not
lead to statistic signiﬁcant differences in costs and
effects.26,27 In contrast, our study clearly states the superior
cost-effectiveness of CBT for RA patients. A possible expla-
nation and important difference between these studies and
ours is that we enrolled patients not only with RA but also
with a diagnosed acute mental disorder, which is actually the
goal of CBT.
Our estimated ratios are negative and the magnitude of
negative cost-effectiveness ratios is not informative. For
example, if an intervention generates E1000 saving for 10
units of effect and an ICER of E100, doubling the effec-
tiveness generates an ICER of E50. This seems economi-
cally less attractive but in reality is a better outcome.28
Moreover, the judgment whether an intervention is con-
sidered cost-effective depends on the willingness of payers
to reimburse additional costs for additional clinical
beneﬁts. For both reasons, we calculated an incremental
1600.001400.001200.001000.00800.00600.00400.00200.000.00
Value of ceiling ratio
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
Pr
ob
ab
ilit
y 
of
 c
os
t-e
ffe
ct
ive
ne
ss
Figure 2 Acceptability curve regarding the probability of superior cost-effectiveness of CBT in comparison to SET. Curve estimated with 1000 bootstrap
replications. The x-axis (values of ceiling ratio) represent a range of maximum monetary values in euros that a decision maker might be willing to pay for an
additional unit of effect.
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cost-effectiveness acceptability curve, which represents the
probability that CBT is cost-effective compared with SET
for a range of maximum monetary values that a decision
maker might be willing to pay for an additional unit of
effect.29,30 Our calculated probability of 90.2% of higher
cost-effectiveness of CBT without the need for additional
costs to payers clearly states the superiority of this interven-
tion in comparison to SET. An even higher probability is
achieved (94.8%) considering quality of life as the effect.
We observed in our study an increase, albeit statistically
non-signiﬁcant, of direct medical costs in the follow-up in
both groups. A possible explanation could be the primary
goal of the intervention, i.e. the reduction of the fear of pro-
gression. This effect was expected to translate into economic
beneﬁts but a reduction of health services utilization was
not directly addressed in the therapy. Indeed, it is traceable
that psychotherapies aiming at improvement of patients’
psychological state cannot be expected to reduce medical
costs to the same degree as interventions that have cost
savings as primary goal.31 Another possible explanation for
the increased costs might be the progressive and debilitating
disease course of RA, which requires intensive medical care.
Limitations of this study
When interpreting the results of our study it is important to
recognize that we preferred to compare two interventions
stead of comparing CBT with no intervention at all. One
consequence of this approach was that it is much harder to
demonstrate statistically signiﬁcant superiority in costs and
effects. The recent development of cost-effectiveness accept-
ability curves reminds us though that the absence of a stat-
istical difference in either costs or effects does not
necessarily mean that two treatments cannot be distin-
guished.32 Indeed, because of the usual low power of econ-
omic evaluations performed alongside randomized clinical
trials, the focus of cost-effectiveness studies should still be
on estimating cost-effectiveness, even when either cost or
effect differences lack conventional statistical signiﬁcance.33
We also recognize that fear of progression, the effect used
in the CEA, is an unusual outcome and eventually difﬁcult
to interpret. However, it is an important outcome because
of its clinical relevance to patients and clinicians. In order to
increase the comparability of our work with the literature,
we decided to estimate an additional ICER using a well
recognized and easier to interpret measure: the mental scale
of the SF-12. Another possibility would have been to esti-
mate QALYs using the SF-12. However, the accuracy of uti-
lities estimated from the SF-12 was recently considered
unsatisfactory, specially for older and less healthy groups,
and inaccurate values can easily bias the conclusion of a
cost-utility-analysis (CUA).34 Additionally, necessary par-
ameters of a representative sample of the German popu-
lation are not available so far. Due to the fact that the
results of a CUA would have been questionable, we decided
to go for a CEA using the SF-12 to increase the compar-
ability of our study with other studies.
Our study has some limitations. First, our economical
evaluation was performed alongside the main trial and is
probably underpowered for the cost-effectiveness analysis.
This is one reason for using bootstrap estimations and cost-
effectiveness acceptability curves. Second, we used a self-
report retrospective standardized questionnaire to collect
information about health-care resource and this kind of data
source is susceptible to recall bias. Third, we extrapolated a
part of the direct cost components to obtain 1 year ﬁgures
conservatively assuming that resource use increases
constantly.
Our main result is the higher cost-effectiveness of CBT in
comparison to SET for our sample of RA patients with high
levels of anxiety. However, the magnitude of the economic
beneﬁts when comparing CBT with no intervention requires
further investigation. Moreover, potential cost savings after
rehabilitative interventions seem to be more likely in indirect
than in the direct costs. For this reason, further economic
evaluations should also focus more closely on the impact of
psychological interventions on productivity loss.
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